Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by David Stuart Morris
Clinical Risk Factors Predicting Genital Fungal Infections With Sodium–glucose Cotransporter 2 Inhibitor Treatment: The ABCD Nationwide Dapagliflozin Audit
Primary Care Diabetes
Internal Medicine
Nutrition
Endocrinology
Dietetics
Metabolism
Diabetes
Related publications
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin
Pharmaceutics
Pharmaceutical Science
Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis
European Scientific Journal ESJ
Increased Grip Strength With Sodium-Glucose Cotransporter 2
Journal of Diabetes
Endocrinology
Metabolism
Diabetes
Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors
Journal of Diabetes
Endocrinology
Metabolism
Diabetes
Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
Diabetes Care
Internal Medicine
Endocrinology
Advanced
Metabolism
Specialized Nursing
Diabetes
Treatment of a Case of Severe Insulin Resistance Due to a PIK3R1 Mutation With a Sodium-Glucose Cotransporter-2 Inhibitor
Journal of Diabetes Investigation
Internal Medicine
Endocrinology
Metabolism
Medicine
Diabetes
Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use
Diabetes Therapy
Internal Medicine
Endocrinology
Metabolism
Diabetes
